Navigation Links
Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance

New tool for planning proton treatments makes it possible to precisely

control how dose is distributed inside the patient's body

PALO ALTO, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) has received FDA 510(k) clearance for a new proton scanning dose algorithm that offers clinicians greater control over how proton beams are used to target tumors and other abnormalities. The new algorithm, which has been incorporated into Varian's Eclipse(TM) treatment planning software, makes it possible to plan for intensity modulated proton therapy by optimizing dose distributions in three dimensions in order to protect surrounding healthy tissues.

This proton scanning technique improves on current proton delivery methods that require a therapist to enter and exit the treatment room numerous times throughout a treatment to adjust physical compensators for processing proton beams. "With proton scanning and intensity-modulation, this cumbersome process can be completely eliminated," said Jeff Amacker, Varian's business manager for treatment planning products.


Proton therapy uses a particle accelerator to generate a beam of protons and deposit them accurately within tumors while sparing adjacent healthy tissues and organs. Unlike the more common photon radiotherapy, with beams that pass all the way through the patient's body, proton therapy beams can be designed to stop and distribute most of their radiation dose at the depth of the tumor. This makes it possible to improve certain cancer treatments by protecting more healthy tissue and thus reduce short- and long-term side effects in cases where surrounding healthy tissues are particularly sensitive to radiation. Radiation oncology experts estimate that about 10 percent of the patients can benefit from having all or some of their treatment with protons.


With the addition of the proton scanning dose algorithm, Eclipse, the fastest, most versatile and widely-used radiotherapy treatment planning system in use today, continues to expand on its functionality as a single system for state-of-the-art proton, photon, electron, and brachytherapy treatment planning. Within the Eclipse planning environment, clinicians can combine and compare plans for any and all of these treatment approaches, to arrive at an optimal strategy for helping each and every patient.


Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,500 people who are located at manufacturing sites in North America and Europe and in its 60 sales and support offices around the world. For more information, visit


Statements in this press release regarding future business, events, plans, objectives, expectations, estimates, and other similar matters, including, but not limited to, statements using the terms "can" and "makes it possible to" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the risks described in the company's Annual Report on Form 10-K and other reports filed from time to time by the Company with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company assumes no obligation to update or revise these forward-looking statements because of new information, future events, or otherwise.


Spencer Sias, (650) 424-5782

Meryl Ginsberg, (650) 424-6444

SOURCE Varian Medical Systems
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Historic Agreement Reached to More Expertly and Efficiently Expand Proton Therapy Worldwide
2. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
3. Loma Linda University to Dedicate Proton Treatment Center to Cancer Therapy Pioneer James M. Slater, M.D.
4. Purdue researchers develop technology to detect cancer by scanning surface veins
5. Algorithms to reanimate the heart
6. Carnegie Mellon algorithm identifies top 100 blogs for news
7. Cranberry Could Juice Up Ovarian Cancer Treatment
8. New Ovarian Cancer Drug Trial Under Way
9. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
10. Pelvic Exams Can Help Spot Ovarian Cancer
11. Study fuels debate over whether exercise and body size influence ovarian cancer risk
Post Your Comments:
(Date:11/27/2015)... ... 27, 2015 , ... A simply groundbreaking television series, "Voices in America", which ... into an array of issues that are presently affecting Americans. Dedicated to providing the ... show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... in central Michigan, have come together on Thanksgiving Day to share the things ... for viewing on the Serenity Point YouTube channel, patients displayed what they wrote ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
Breaking Medicine Technology: